# Kisoji Biotechnology

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kisoji-biotechnology

- Industry: Biotechnology
- Headquarters: Montreal, Canada
- Website: www.kisojibiotech.com
- Total disclosed funding: $41M
- Latest round: Series B (Dec 2, 2024)
- Investors on record: 9

## About

Based in Canada, Kisoji Biotechnology Inc. focuses on the development of advanced antibody therapeutics aimed at addressing complex challenges in oncology and related fields through innovative technology platforms.Kisoji Biotechnology Inc. specializes in therapeutic antibody discovery and development. Founded in Montreal, Canada, the company has successfully secured funding through various rounds, with its most recent being a CAD 57.39 mn Series B round on December 2, 2024, co-led by Investment Quebec and Lumira Ventures. The lead founder has a background in biotechnology with previous entrepreneurial endeavors, enhancing the company's strategic direction. The firm operates out of Montreal, where it has established a base for its global operations.Kisoji Biotechnology Inc. specializes in the discovery and development of advanced antibody therapeutics designed to address challenging targets, particularly in oncology and other complex diseases. Their proprietary platform enhances antibody discovery through the use of single domain antibodies derived from transgenic mice, allowing for comprehensive visualization of the immune response. The flagship product, a novel TROP2 antibody, shows therapeutic efficacy devoid of drug conjugates, catering primarily to biopharmaceutical companies focused on oncology and immunotherapy in North America and Europe.Kisoji Biotechnology operates on a business model that emphasizes strategic partnerships and collaborations. Revenue is generated through licensing their proprietary antibody platform and the development of multi-specific antibodies. Collaborative agreements enable clients to co-develop innovative therapeutics, utilizing Kisoji's advanced technologies. The TROP2 antibody program is a pivotal offering, likely involving milestone payments and potential royalties from commercialization, structured to align financially with successful therapeutic advancements.In December 2024, Kisoji Biotechnology Inc. raised CAD 57.39 mn in Series B funding, which will be utilized to advance the research and development of therapeutic antibody drugs for cardiometabolic diseases, immunology, and inflammation. The company plans to expand its product offerings, focusing on innovative drugs slated for launch in the upcoming year, and aims to penetrate new markets across North America and Europe by 2025, leveraging its recent funding to enhance research capabilities and foster strategic partnerships.

## Funding rounds

- Series B, Dec 2, 2024, $41M — Investment Quebec, Remiges Ventures, adMare Bioinnovations, Fonds de solidarite FTQ, Lumira Ventures
- Series A, Jun 8, 2018 — Remiges Ventures, Fonds de solidarité FTQ Investissements, Lumira Ventures
- Series A, Jul 4, 2016 — BDC Capital, Accel-Rx Health Sciences Accelerator, Fonds de solidarité FTQ Investissements, Centre for Commercialization of Regenerative Medicine, Lumira Ventures

## Investors

- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A
- Accel-Rx Health Sciences Accelerator — Series A
- Fonds de solidarité FTQ Investissements — Series A
- Centre for Commercialization of Regenerative Medicine — Series A
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series A, Series B
- Remiges Ventures (https://capitalatlas.ai/funds/remiges-ventures) — Series A, Series B
- Investment Quebec (https://capitalatlas.ai/funds/investment-quebec) — Series B
- adMare Bioinnovations (https://capitalatlas.ai/funds/admare-bioinnovations) — Series B
- Fonds de solidarite FTQ (https://capitalatlas.ai/funds/fonds-de-solidarite-ftq) — Series B